Journal

UK pharmacists need three things from digital tools: GPhC CRA revision support, clinical reference during practice, and CPD tracking for revalidation. This guide covers what iatroX...

Non-medical prescribers — nurses, pharmacists, and paramedics completing independent prescribing qualifications — have no dedicated Q-bank for the prescribing assessment. This guid...

Independent prescribing for pharmacists is now a regulatory requirement for new graduates under the IETP 2021 standards — and a career-transforming credential for experienced pharm...

MDCalc is the default clinical calculator for most doctors — but it defaults to US guidelines. UK practice needs QRISK3 not Pooled Cohort Equations, NICE-referenced CURB-65 pathway...

Nurses pursuing the DFSRH follow the same programme as doctors — but the practical realities of access, clinical placements, prescribing scope, and career application differ. This ...

Not a health policy comparison. A practical, day-to-day guide to the differences a UK GP will notice from week one in Canada — billing, referrals, prescribing, and patient expectat...

Every UK medical student sits the PSA. Most overthink it. Here's the format, what actually matters, and how to prepare efficiently.

Neither MetaGuideline nor Medicaite is a Q-bank. Neither is a learning platform. Yet trainees are using prescribing copilots as revision tools and clinical reference as exam prep. ...

Guideline-harmonising AI like MetaGuideline delivers fast, synthesised prescribing recommendations — but fast answers are not the same as source mastery. This article explains why ...

Rebuilt as the pillar guide: the best AI tool for a prescriber is the one that makes evidence, uncertainty, jurisdiction and limits easiest to inspect; task-based recommendations a...

MetaGuideline harmonises guidelines for prescribing decisions. OpenEvidence synthesises research literature for evidence queries. iatroX retrieves UK guideline-grounded answers wit...

AI prescribing tools may help organise complex multi-condition medication logic, but the path from product information to a multimorbidity decision still requires evidence appraisa...